Posts

Posted on

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire

ANDOVER, Mass., Dec. 24, 2025 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 6,333 shares of its common stock and an aggregate of 4,205 restricted stock units to 5 employees, each as a material inducement for each employee’s entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

TransMedics granted non-qualified stock options to purchase 6,333 shares of TransMedics’ common stock and 4,205 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $129.35, the closing price of the common stock on the Nasdaq Global Market on December 22, 2025. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee’s start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee’s continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee’s start of employment, subject to the employee’s continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.

About TransMedics Group, Inc.
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302649296.html

SOURCE TransMedics Group, Inc.

Posted on

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date December 15, 2025

NEW YORK, Dec. 24, 2025 (GLOBE NEWSWIRE) — At the end of the settlement date of December 15, 2025, short interest in 3,486 Nasdaq Global MarketSM securities totaled 15,012,659,234 shares compared with 14,879,370,342 shares in 3,453 Global Market issues reported for the prior settlement date of November 28, 2025. The mid-December short interest represents 2.90 days compared with 2.22 days for the prior reporting period.

Short interest in 1,683 securities on The Nasdaq Capital MarketSM totaled 3,369,741,795 shares at the end of the settlement date of December 15, 2025, compared with 3,311,934,829 shares in 1,698 securities for the previous reporting period. This represents a 1.29 day average daily volume; the previous reporting period’s figure was 1.00.

In summary, short interest in all 5,169 Nasdaq® securities totaled 18,382,401,029 shares at the December 15, 2025 settlement date, compared with 5,151 issues and 18,191,305,171 shares at the end of the previous reporting period. This is 2.36 days average daily volume, compared with an average of 1.82 days for the prior reporting period.

The open short interest positions reported for each Nasdaq security reflect the total number of shares sold short by all broker/dealers regardless of their exchange affiliations. A short sale is generally understood to mean the sale of a security that the seller does not own or any sale that is consummated by the delivery of a security borrowed by or for the account of the seller.

For more information on Nasdaq Short interest positions, including publication dates, visit http://www.nasdaq.com/quotes/short-interest.aspx or http://www.nasdaqtrader.com/asp/short_interest.asp.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Media Contact:

Sam Raffalli
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bacf58c2-29b5-48ef-8618-a4e4088a92e2

NDAQO



Posted on

Resources Connection to Announce Second Quarter Fiscal 2026 Results on January 7, 2026

Resources Connection to Announce Second Quarter Fiscal 2026 Results on January 7, 2026

DALLAS–(BUSINESS WIRE)–
Resources Connection, Inc. (Nasdaq: RGP) (the “Company,” “we,” and “our”), a global consulting firm, will announce results of operations for its second quarter of fiscal 2026 ended November 29, 2025, after the close of market on Wednesday, January 7, 2026.

This release will be followed by a conference call at 5:00 p.m. ET, January 7, 2026. A live webcast of the call will be available on the “Investor Relations” Events section of the Company’s website. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time by visiting the RGP Investor Events section of the Company’s website.

ABOUT RGP

RGP (Nasdaq: RGP) is an award-winning global professional services firm with three decades of experience helping the world’s top organizations navigate change and seize opportunity. With three integrated offerings—On-Demand Talent, Consulting, and Outsourced Services—we provide CFOs and C-suite leaders with the flexibility to solve today’s most pressing challenges on their terms, uniting strategy, execution, and talent across accounting and finance, digital transformation, data, and cloud, at a global scale. Our people-first approach continues to drive innovation across industries worldwide.

Based in Dallas, Texas, with offices worldwide, we annually engage with over 1,600 clients around the world from 41 physical practice offices and multiple virtual offices. As of May 2025, RGP is proud to have served 88 percent of the Fortune 100 and has been recognized by U.S. News & World Report (2024–2025 Best Companies to Work For) and Forbes (America’s Best Management Consulting Firms 2025, America’s Best Midsize Employers 2025, World’s Best Management Consulting Firms 2024).

The Company is listed on the Nasdaq Global Select Market, the exchange’s highest tier by listing standards. To learn more about RGP, visit: http://www.rgp.com.

Investor Contact:

Jennifer Ryu, Chief Financial Officer

(US+) 1-714-430-6500

[email protected]

Media Contact:

Pat Burek

Financial Profiles

(US+) 1-310-622-8244

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Consulting Communications Professional Services Public Relations/Investor Relations

MEDIA:

Logo
Logo
Posted on

SCULLY ROYALTY ISSUES FURTHER UPDATE ON ANNUAL SHAREHOLDERS’ MEETING AND COURT PROCEEDINGS

PR Newswire

NEW YORK, Dec. 24, 2025 /PRNewswire/ — Further to its news release dated December 22, 2025, Scully Royalty Ltd. (the “Company”) (NYSE: SRL) announces that it has filed an appeal of the December 19, 2025 decision of the Grand Court of the Cayman Islands with respect to the notice of nomination of MILFAM LLC (“MILFAM”) and its compliance with the timing requirements under the Memorandum and Articles of Association of the Company.

The Company further announces that its annual general meeting (the “Meeting”), originally scheduled for December 27, 2025, has been temporarily postponed for a short duration of time to allow a hearing before the Cayman Islands Court of Appeal to be heard as soon as practicable. The Company is inviting MILFAM to work collaboratively and in good faith with the Company in this endeavor.

The postponement was approved by the Company’s board of directors, based on the recommendation of its Compensation, Nominating and Corporate Governance Committee. In determining to postpone the Meeting, such committee and the board considered various factors relating to the best interests of the Company and its shareholders and the circumstances of the Meeting, including, among other things, that a short postponement will assist in addressing the uncertainty created by the recent decision and appeal, the need to provide shareholders sufficient opportunity to assess the purported nominations of MILFAM pending the outcome of the court proceedings, and to allow the Meeting to take place in an orderly manner that promotes and is conductive of informed shareholder decision-making with full disclosure by each party of all material information.

Cision View original content:https://www.prnewswire.com/news-releases/scully-royalty-issues-further-update-on-annual-shareholders-meeting-and-court-proceedings-302649376.html

SOURCE Scully Royalty Ltd.

Posted on

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated December 22, 2025, notifying the Company that based on XTL’s closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

The Nasdaq notification letter does not result in the immediate delisting of the Company’s American Depositary Shares (“ADSs”), and the ADSs will continue to trade uninterrupted under the symbol “XTLB”.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 22, 2026, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide XTL with written confirmation of compliance and this matter will be closed.

In the event the Company does not regain compliance, XTL may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If XTL meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

XTL is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirements. Although XTL will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.

About XTL Biopharmaceuticals Ltd.

XTL is an IP portfolio company.  XTL holds 100% of the share capital of The Social Proxy Ltd. (the “Social Proxy”), a web data company, and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease. The Social Proxy is a web data AI company, developing and powering a unique ethical, IP based, proxy data extraction platform for AI and BI applications at scale.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; and (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: [email protected]
www.xtlbio.com



Posted on

INSP INVESTOR ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut

PR Newswire

Partner Reed Kathrein Urges Investors to Contact Firm Before January 5, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Dec. 24, 2025 /PRNewswire/ — National investor rights law firm Hagens Berman alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP). The firm is urging INSP investors who suffered substantial losses to contact its attorneys before the January 5, 2026, Lead Plaintiff Deadline. The lawsuit, which is currently pending in the U.S. District Court for the District of Minnesota, alleges that Inspire Medical and its executives misled investors by concealing critical operational failures surrounding the launch of its next-generation device, the Inspire V for obstructive sleep apnea.

Class Period: Investors who purchased Inspire Medical (INSP) securities between August 6, 2024, and August 4, 2025.

Lead Plaintiff Deadline:
January 5, 2026


Submit Your INSP Losses Now
: If you suffered a substantial loss on your INSP investment, you are encouraged to contact Hagens Berman Partner Reed Kathrein to discuss your legal rights:

Visit: www.hbsslaw.com/investor-fraud/insp Email:[email protected]Call:844-916-0895

The Heart of the Inspire Medical Systems (INSP) Fraud Allegations

The securities class action complaint details how Inspire Medical allegedly assured investors of its “operational readiness” for the Inspire V launch, claiming it was ready “to throw the switch” for full commercial rollout. These assurances, the lawsuit contends, concealed fundamental failures that made a successful launch impossible, leading to a catastrophic guidance cut and stock crash.

The undisclosed operational issues that allegedly rendered the Company’s statements materially false and misleading include:



Alleged Concealment


The Truth Allegedly Revealed on Aug. 4, 2025


Impact on Business/Stock


Medicare & Billing Readiness

The necessary software updates for Medicare claims processing did not take effect until July 1, 2025, meaning implanting centers could not bill for procedures, stalling early adoption.

Delayed Inspire V rollout and bottlenecked revenue generation.


Excess Inventory (Channel Glut)

Customers and treatment centers held a significant surplus of the older Inspire IV device, impacting demand for the new Inspire V product and requiring an inventory “burn down.”

The allegedly flawed Inspire V launch led Inspire to slash its 2025 EPS guidance by over 80%.


Training & Onboarding

“Many centers” had not completed the essential training, contracting, and onboarding required to implant the new device.


$42.04 per share drop and 32.4% decline in value.

Hagens Berman’s Investigation of the Alleged Claims

“Our focus remains on the alleged concealment of two critical points: the Medicare claims software failure and the inventory glut of the prior Inspire IV device,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation. “The suit alleges that Inspire’s stock collapse was the result of management allegedly prioritizing a narrative of seamless transition over operational reality.”

What You Can Do?: If you purchased Inspire Medical (INSP) securities during the Class Period, you may have legal options. If you wish to discuss your rights or have information that may assist our investigation, please contact Hagens Berman

If you’d like more information and answers to frequently asked questions about the Inspire case and our investigation, visit Hagens Berman’s INSP dedicated case page: www.hbsslaw.com/investor-fraud/insp »

Whistleblowers: Persons with non-public information regarding Inspire should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insp-investor-alert-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures–inspire-v-inventory-glut-302649363.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

Primo Brands Corporation (PRMB) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

BENSALEM, Pa., Dec. 24, 2025 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Primo Brands Corporation (“Primo Brands” or the “Company”) (NYSE: PRMB).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PRIMO BRANDS CORPORATION (PRMB),
CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JANUARY 12, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between June 17, 2024 and November 6, 2025, Defendants failed to disclose to investors that: (1) the merger integration between Primo Water and BlueTriton Brands was tracking poorly due to, among other things, technology and service issues; (2) the Company was having major supply disruptions which would negatively impact customers and thus the Company’s financial results; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/primo-brands-corporation-prmb-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302649367.html

SOURCE Law Offices of Howard G. Smith

Posted on

Perrigo Company plc (PRGO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

BENSALEM, Pa., Dec. 24, 2025 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PERRIGO COMPANY PLC (PRGO),
CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JANUARY 16, 2026
(LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between February 27, 2023 and November 4, 2025, Defendants failed to disclose to investors: (1) that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; (4) that, as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:  
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/perrigo-company-plc-prgo-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302649368.html

SOURCE Law Offices of Howard G. Smith

Posted on

Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

LOS ANGELES, Dec. 24, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX).

IF YOU SUFFERED A LOSS ON YOUR TELIX INVESTMENTS, CLICK HERE BEFORE JANUARY 9, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between February 21, 2025 and August 28, 2025, Defendants failed to disclose to investors that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/telix-pharmaceuticals-limited-tlx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302649365.html

SOURCE Glancy Prongay & Murray LLP

Posted on

DeFi Technologies Inc. (DEFT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire

LOS ANGELES, Dec. 24, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against DeFi Technologies Inc. (“DeFi” or the “Company”) (NASDAQ: DEFT).

IF YOU SUFFERED A LOSS ON YOUR DEFI INVESTMENTS, CLICK HERE
BEFORE JANUARY 30, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between May 12, 2025 and November 14, 2025, Defendants failed to disclose to investors that: (1) DeFi was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (2) DeFi had understated the extent of competition it faced from other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (3) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (4) accordingly, Defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies’ business and financial results; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/defi-technologies-inc-deft-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302649364.html

SOURCE Glancy Prongay & Murray LLP